Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

[¹¹C]Sorafenib: radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer.

Poot AJ, van der Wildt B, Stigter-van Walsum M, Rongen M, Schuit RC, Hendrikse NH, Eriksson J, van Dongen GA, Windhorst AD.

Nucl Med Biol. 2013 May;40(4):488-97. doi: 10.1016/j.nucmedbio.2013.02.002. Epub 2013 Mar 20.

2.

Early detection and longitudinal monitoring of experimental primary and disseminated melanoma using [¹⁰F]ICF01006, a highly promising melanoma PET tracer.

Rbah-Vidal L, Vidal A, Besse S, Cachin F, Bonnet M, Audin L, Askienazy S, Dollé F, Degoul F, Miot-Noirault E, Moins N, Auzeloux P, Chezal JM.

Eur J Nucl Med Mol Imaging. 2012 Sep;39(9):1449-61. doi: 10.1007/s00259-012-2168-y. Epub 2012 Jun 16.

PMID:
22707183
3.

Synthesis and preclinical evaluation of [(11)C]PAQ as a PET imaging tracer for VEGFR-2.

Samén E, Thorell JO, Lu L, Tegnebratt T, Holmgren L, Stone-Elander S.

Eur J Nucl Med Mol Imaging. 2009 Aug;36(8):1283-95. doi: 10.1007/s00259-009-1111-3. Epub 2009 Mar 14.

PMID:
19288096
4.

Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors.

Slobbe P, Windhorst AD, Stigter-van Walsum M, Schuit RC, Smit EF, Niessen HG, Solca F, Stehle G, van Dongen GA, Poot AJ.

Nucl Med Biol. 2014 Oct;41(9):749-57. doi: 10.1016/j.nucmedbio.2014.06.005. Epub 2014 Jun 25.

PMID:
25066021
5.

Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma.

Muselaers CH, Stillebroer AB, Desar IM, Boers-Sonderen MJ, van Herpen CM, de Weijert MC, Langenhuijsen JF, Oosterwijk E, Leenders WP, Boerman OC, Mulders PF, Oyen WJ.

J Nucl Med. 2014 Feb;55(2):242-7. doi: 10.2967/jnumed.113.131110. Epub 2014 Jan 6.

6.

Radiosynthesis, biodistribution and imaging of [11C]YM155, a novel survivin suppressant, in a human prostate tumor-xenograft mouse model.

Murakami Y, Matsuya T, Kita A, Yamanaka K, Noda A, Mitsuoka K, Nakahara T, Miyoshi S, Nishimura S.

Nucl Med Biol. 2013 Feb;40(2):221-6. doi: 10.1016/j.nucmedbio.2012.10.002. Epub 2012 Nov 7.

PMID:
23141550
7.

A PET Tracer for Brain α2C Adrenoceptors, (11)C-ORM-13070: Radiosynthesis and Preclinical Evaluation in Rats and Knockout Mice.

Arponen E, Helin S, Marjamäki P, Grönroos T, Holm P, Löyttyniemi E, Någren K, Scheinin M, Haaparanta-Solin M, Sallinen J, Solin O.

J Nucl Med. 2014 Jul;55(7):1171-7. doi: 10.2967/jnumed.113.135574. Epub 2014 May 5.

8.

Fluorine-18 click radiosynthesis and preclinical evaluation of a new 18F-labeled folic acid derivative.

Ross TL, Honer M, Lam PY, Mindt TL, Groehn V, Schibli R, Schubiger PA, Ametamey SM.

Bioconjug Chem. 2008 Dec;19(12):2462-70. doi: 10.1021/bc800356r.

PMID:
19053298
9.

Radiosynthesis and biological evaluation of 5-(3-[18F]fluoropropyloxy)-L-tryptophan for tumor PET imaging.

He S, Tang G, Hu K, Wang H, Wang S, Huang T, Liang X, Tang X.

Nucl Med Biol. 2013 Aug;40(6):801-7. doi: 10.1016/j.nucmedbio.2013.04.013. Epub 2013 Jun 20.

PMID:
23791401
10.

Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography.

Pal A, Glekas A, Doubrovin M, Balatoni J, Namavari M, Beresten T, Maxwell D, Soghomonyan S, Shavrin A, Ageyeva L, Finn R, Larson SM, Bornmann W, Gelovani JG.

Mol Imaging Biol. 2006 Sep-Oct;8(5):262-77. Erratum in: Mol Imaging Biol. 2006 Nov-Dec;8(6):373. Namavari, Mohammed [added].

PMID:
16897320
11.

Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.

Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR, Giaccone G, Albano R, Comoglio PM, van Dongen GA.

Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1857-67. doi: 10.1007/s00259-008-0774-5. Epub 2008 May 20.

PMID:
18491091
12.

68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.

Persson M, Madsen J, Østergaard S, Ploug M, Kjaer A.

Nucl Med Biol. 2012 May;39(4):560-9. doi: 10.1016/j.nucmedbio.2011.10.011. Epub 2011 Dec 14.

PMID:
22172391
13.

PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET.

Slobbe P, Poot AJ, Windhorst AD, van Dongen GA.

Drug Discov Today. 2012 Nov;17(21-22):1175-87. doi: 10.1016/j.drudis.2012.06.016. Epub 2012 Jul 2. Review.

PMID:
22766374
14.

Evaluation of deuterated 18F- and 11C-labeled choline analogs for cancer detection by positron emission tomography.

Witney TH, Alam IS, Turton DR, Smith G, Carroll L, Brickute D, Twyman FJ, Nguyen QD, Tomasi G, Awais RO, Aboagye EO.

Clin Cancer Res. 2012 Feb 15;18(4):1063-72. doi: 10.1158/1078-0432.CCR-11-2462. Epub 2012 Jan 10.

15.

A novel PET tracer for the imaging of αvβ3 and αvβ5 integrins in experimental breast cancer bone metastases.

Mühlhausen U, Komljenovic D, Bretschi M, Leotta K, Eisenhut M, Semmler W, Bäuerle T.

Contrast Media Mol Imaging. 2011 Nov-Dec;6(6):413-20. doi: 10.1002/cmmi.435.

PMID:
22162137
16.

Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma.

Murakami M, Zhao S, Zhao Y, Chowdhury NF, Yu W, Nishijima K, Takiguchi M, Tamaki N, Kuge Y.

Int J Oncol. 2012 Nov;41(5):1593-600. doi: 10.3892/ijo.2012.1624. Epub 2012 Sep 10.

17.

Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.

Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, Bading JR, Laug WE, Conti PS.

J Nucl Med. 2004 Oct;45(10):1776-83.

18.

Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts.

Tsuji AB, Sogawa C, Sugyo A, Sudo H, Toyohara J, Koizumi M, Abe M, Hino O, Harada YN, Furukawa T, Suzuki K, Saga T.

Nucl Med Biol. 2009 May;36(4):379-88. doi: 10.1016/j.nucmedbio.2009.01.018. Epub 2009 Mar 26.

PMID:
19423005
19.

Multimodal imaging of tumor response to sorafenib combined with radiation therapy: comparison between diffusion-weighted MRI, choline spectroscopy and 18F-FLT PET imaging.

Karroum O, Mignion L, Kengen J, Karmani L, Levêque P, Danhier P, Magat J, Bol A, Labar D, Grégoire V, Bouzin C, Feron O, Gallez B, Jordan BF.

Contrast Media Mol Imaging. 2013 May-Jun;8(3):274-80. doi: 10.1002/cmmi.1525.

PMID:
23606431
20.

Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma.

Zhang QB, Sun HC, Zhang KZ, Jia QA, Bu Y, Wang M, Chai ZT, Zhang QB, Wang WQ, Kong LQ, Zhu XD, Lu L, Wu WZ, Wang L, Tang ZY.

PLoS One. 2013;8(2):e55945. doi: 10.1371/journal.pone.0055945. Epub 2013 Feb 8.

Items per page

Supplemental Content

Write to the Help Desk